DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: pramlintide acetate

Summary for Generic Name: pramlintide acetate

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers: see list1
Therapeutic Class:Blood Glucose Regulators

Pharmacology for Ingredient: pramlintide acetate

Drug ClassAmylin Analog
Mechanism of ActionAmylin Agonists

Clinical Trials for: pramlintide acetate

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
Status: Completed Condition: Overweight; Obesity

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Status: Completed Condition: Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
Status: Completed Condition: Type 1 Diabetes Mellitus

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
Status: Completed Condition: Overweight; Obesity

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
Status: Completed Condition: IDDM

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
Status: Active, not recruiting Condition: Type 1 Diabetes

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus
Status: Active, not recruiting Condition: Type 2 Diabetes Mellitus

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Status: Completed Condition: Obesity

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Status: Recruiting Condition: Hypoglycemia; Evidence of Previous Gastric Surgery

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes
Status: Recruiting Condition: Type 2 Diabetes

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXNo5,686,411<disabled>YYTREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXNo5,814,600<disabled>TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXNo5,814,600<disabled>TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXNo5,814,600<disabled>TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc